| Abstract: |
To evaluate the efficacy of monthly or quarterly fremanezumab in patients with chronic migraine or episodic migraine and documented inadequate response to 2, 3, or 4 classes of prior migraine preventive medications. This is an exploratory analysis of a randomized, double-blind, placebo-controlled, phase 3b trial for patients with chronic migraine or episodic migraine and inadequate response to 2 to 4 prior migraine preventive medication classes randomized (1:1:1) to fremanezumab (quarterly or monthly) or placebo. In this exploratory analysis, changes from baseline in the monthly average number of migraine days during 12 weeks of double-blind treatment and adverse events were evaluated for predefined subgroups of patients by number of prior preventive medication classes with inadequate response. Overall, 414, 265, and 153 patients had inadequate response to 2, 3, and 4 preventive medication classes, respectively. Changes from baseline in monthly average migraine days during 12 weeks were significantly greater with fremanezumab compared with placebo for patients with documented inadequate response to 2 classes (least-squares mean difference vs placebo [95% confidence interval]: quarterly, -2. 9 [-3. 83, -1. 98]; monthly, -3. 7 [-4. 63, -2. 75]), 3 classes (quarterly, -3. 3 [-4. 65, -1. 95]; monthly, -3. 0 [-4. 25, -1. 66]), and 4 classes (quarterly, -5. 3 [-7. 38, -3. 22]; monthly, -5. 4 [-7. 35, -3. 48]) of migraine preventive medications (all p < 0. 001). No significant treatment-by-subgroup interactions were observed for any outcome (p interaction > 0. 20 for all). Adverse events were comparable for placebo and fremanezumab. Significant improvements in efficacy were observed with fremanezumab compared with placebo, even in patients who had previously experienced inadequate response to 4 different classes of migraine preventive medications. ClinicalTrials. gov identifier: NCT03308968. |
guest ::
(Vestra Clinics (República Txeca))
